The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
Life Science Institute to Begin Exploratory Study of Muse Cell Therapy for COVID-19-Associated ARDS
Life Science Institute, a Mitsubishi Chemical group company, will kick off a Japanese exploratory clinical study of its multi-lineage differentiating stress enduring (Muse) cell therapy CL2020 for the treatment of acute respiratory distress syndrome (ARDS) associated with COVID-19 as early…
To read the full story
Related Article
- Life Science Institute to Establish New Field of Reparative Medicine with Muse Cells: President
May 20, 2021
- Life Science Institute to Test Muse Cell Therapy in ALS
January 29, 2021
- Life Science Institute’s Muse Cell Therapy Effective in Epidermolysis Bullosa
July 30, 2020
- Life Science Institute’s Muse Cell Product Shows Safety, Tolerability in 2 Trials
April 24, 2020
- Life Science Institute Begins Muse Cell Trial for Spinal Injury; President Confident of Profitability
July 10, 2019
- Life Science Institute Initiates Exploratory Clinical Trial of Muse Cell Product for Epidermolysis Bullosa
December 21, 2018
- Life Science Institute to Initiate Exploratory Clinical Study of Muse Cell Product for Cerebral Infarction
September 4, 2018
- Life Science Institute Launches Clinical Study of IV Regenerative Medicine Product for Acute Myocardial Infarction
January 18, 2018
BUSINESS
- Pharma Hails End to “Spillover” Rule, Vows to Keep Fighting Off-Year Cuts
December 25, 2025
- Drug Wholesalers Slam “No-Discussion” Decision on FY2027 Off-Year Price Revision
December 25, 2025
- JCR Earns Japan Rights to DMD Drug from Italfarmaco
December 25, 2025
- Fujifilm Completes Major Biologics CDMO Plant in Toyama, Eyes 2027 Start-Up
December 25, 2025
- Alfresa’s Cell Resources Inks Partnership with Korea’s ENCell
December 25, 2025
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…